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the original work isObjective: Preexposure prophylaxis (PrEP) offers a promising new approach to HIV
prevention. This systematic review and meta-analysis evaluated the evidence for use of
oral PrEP containing tenofovir disoproxil fumarate as an additional HIV prevention
strategy in populations at substantial risk for HIV based on HIV acquisition, adverse
events, drug resistance, sexual behavior, and reproductive health outcomes.
Design: Rigorous systematic review and meta-analysis.
Methods: A comprehensive search strategy reviewed three electronic databases and
conference abstracts through April 2015. Pooled effect estimates were calculated using
random-effects meta-analysis.
Results: Eighteen studies were included, comprising data from 39 articles and six
conference abstracts. Across populations and PrEP regimens, PrEP significantly reduced
the risk of HIV acquisition compared with placebo. Trials with PrEP use more than 70%
demonstrated the highest PrEP effectiveness (risk ratio¼0.30, 95% confidence interval:
0.21–0.45, P<0.001) compared with placebo. Trials with low PrEP use did not show a
significantly protective effect. Adverse events were similar between PrEP and placebo
groups. More cases of drug-resistant HIV infection were found among PrEP users who
initiated PrEP while acutely HIV-infected, but incidence of acquiring drug-resistant HIV
during PrEP use was low. Studies consistently found no association between PrEP use
and changes in sexual risk behavior. PrEP was not associated with increased pregnancy-
related adverse events or hormonal contraception effectiveness.
Conclusion: PrEP is protective against HIV infection across populations, presents few
significant safety risks, and there is no evidence of behavioral risk compensation. The
effective and cost-effective use of PrEP will require development of best practices for
fostering uptake and adherence among people at substantial HIV risk.
Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2016, 30:1973–1983Keywords: HIV, HIV prevention, meta-analysis, preexposure prophylaxis,
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1973
1974 AIDS 2016, Vol 30 No 12recommended offering oral PrEP containing tenofovir
disoproxil fumarate (TDF) among HIV serodiscordant
couples and MSM, with the conditionality that
demonstration projects were needed to ascertain optimal
delivery approaches and target groups [2]. In 2014, these
recommendations were integrated into consolidated HIV
guidelines for key populations, including a strong
recommendation for offering PrEP as a prevention
option for MSM [3]. However, as experience with PrEP
across populations from clinical trials, demonstration
projects, and clinical practice has grown, so has the need
to evaluate PrEP among all people at high HIV risk. To
date, no systematic assessment of PrEP’s effectiveness
across populations exists. We conducted this systematic
review and meta-analysis of the effectiveness of oral
PrEP containing TDF for all people at substantial risk of
HIV [4].Methods
Search strategy and inclusion criteria
For inclusion, a study had to: be a randomized controlled
trial (RCT), an open-label extension (OLE), or a
demonstration project evaluating oral PrEP containing
TDF to prevent HIV infection; measure one or more key
outcomes, comparing those randomized to PrEP vs.
placebo or those receiving PrEP vs. no PrEP use (i.e.,
delayed PrEP); and be published in a peer-reviewed
journal or presented at a scientific conference between 1
January 1990 and 15 April 2015. Key outcomes included:
HIV infection, adverse events, antiretroviral drug
resistance, reproductive health (hormonal contraception
effectiveness and adverse pregnancy-related events), and
behavior (condom use and number of sexual partners).
We followed Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Guidelines for reporting
systematic reviews and meta-analyses [5].
Our search strategy included electronic databases,
scientific conference websites, and secondary searching
of included studies. We searched PubMed, Cumulative
Index to Nursing and Allied Health Literature, and
Embase using predetermined search terms (available from
authors upon request). For conferences, we searched
abstracts from the International AIDS Conference (IAC),
International AIDS Society (IAS) Conference on HIV
Pathogenesis, Treatment, and Prevention, and Confer-
ence on Retroviruses and Opportunistic Infections. For
IAS/IAC, we searched conferences from 2006 to 2014.
For CROI, only abstracts from 2014 to 2015 were
publicly available. We also conducted iterative secondary
reference searching on all included studies.
Data abstraction and management
Study authors initially screened titles, abstracts, and study
descriptors of identified citations. Two independentreviewers screened the remaining citations, obtained full
text articles, and independently extracted data from
included studies using standardized forms. Differences in
data extraction were resolved through consensus. For
RCTs, we evaluated risk of bias using the Cochrane
Collaboration’s risk assessment tool [6].
Analysis
We conducted meta-analysis using random-effects
models with Comprehensive Meta-Analysis v3.0, check-
ing sensitivity by running primary analyses with and
without certain studies with predetermined character-
istics, including adherence. In meta-analysis, we stratified
by study design (e.g. RCT or observational) and
comparator (e.g., placebo or delayed PrEP).
Because this review covered multiple populations, drug
regimens, dosing schemes, and comparators, we con-
ducted subgroup analyses identified a priori, including
biological sex, age (<25 or 25 years), primary mode of
sexual HIV acquisition (rectal or penile/vaginal
exposure), adherence level, PrEP dosing (daily or
intermittent), and regimen [TDF alone or in combi-
nation with emtricitabine (FTC/TDF)]. We performed
subgroup analyses only among studies presenting stratified
data; participant-level data were not analyzed. We defined
studies’ overall adherence level based on the percentage of
HIV-negative participants receiving PrEP with discern-
ible levels of study medication in their blood when
sampled. Studies presenting this information, usually as
part of a case-control or case-cohort analysis, also
presented results of detectable drug levels found among
seroconverters (Table 9S, http://links.lww.com/QAD/
A928). If studies did not report blood-based drug
detection, they were excluded from this analysis. Trial-
level adherence levels were divided into three categories
with ‘high’ adherence defined as more than 70%,
‘moderate’ as 41–70%, and ‘low’ as 40% or less drug
detection. When possible we used Comprehensive Meta-
Analysis v3.0 to conduct bivariate method of moments
random-effects meta-regression to evaluate whether
variables moderated the effect of PrEP on reducing risk
of HIV infection.Results
Description of included studies
Of 3068 citations screened, 39 articles and six conference
abstracts covering 18 PrEP-related studies were included
(Fig. 1). We included 15 RCTs and three observational
OLE or demonstration projects (Table 1). Seven RCTs
were double-blind placebo-controlled trials evaluating
the efficacy and safety of daily oral PrEP
[8,18,24,32,45,47,49]. Two studies randomized partici-
pants to receive immediate or delayed PrEP [13,43], and
one study compared daily PrEP with both placebo and
Effectiveness of oral preexposure prophylaxis Fonner et al. 1975
Records identified
through database
searching (N = 3900)
Conference
abstracts
identified
(N = 296)
Records screened (N = 3068)
Records after duplicates removed (N = 3068)
Full-text articles assessed for
eligibility (N = 434)
Records excluded after first
review (N = 2384)
Abstracts excluded after first
review (N = 250) 
Studies included in the review
(N = 18 studies from 39 articles
and 6 conference abstracts)
Full-text articles excluded
(N = 389) because:
 •   Did not meet study inclusion
     criteria or presented
     preliminary/ overlapping data
     with primary studies (N = 26)
 •   Coded as background  (N = 175)
 •   Coded as values and
     preferences (N = 188)
Additional records
identified through other
sources (N = 2)
Fig. 1. Disposition of study citations during searching and screening process.‘no-pill’ arms [42]. Several trials examined alternative
PrEP dosing strategies [21,30,31], including nondaily
PrEP (taken before and after sexual intercourse). Two
open-label RCTs compared different PrEP regimens and
dosing strategies with no placebo arm [7,40]. Three
demonstration projects and OLE continuations from
previous RCTs were also included [11,29,41].
Included studies involved 19 491 participants, of whom
11 901 received active PrEP, with follow-up times
ranging from 24 weeks to 5 years. Populations included
people who inject drugs, serodiscordant couples, MSM
and transgender women, women, and heterosexual men.
Trials occurred in low, middle and high-income settings.
Overall RCTs were judged to have low risk of bias (Table
1S, http://links.lww.com/QAD/A928). Several studies
had unclear risk for reporting bias, either because study
protocols were not publicly accessible or available data
included only preliminary results. Overall adherence
levels, as measured by drug detection, were exceptionally
low in two studies, FEM-PrEP and VOICE [18,47],
which compromised their ability to accurately assess
PrEP effectiveness.
HIV infection
HIV infection was measured in 11 RCTs comparing
PrEP with placebo, three RCTs comparing PrEP with no
PrEP (e.g. delayed PrEP or ‘no pill’), and three
observational studies. Across placebo-controlled trials(Table 2a, Fig. 2), results from meta-analysis demonstrated
a 51% reduction in risk of HIV infection comparing PrEP
with placebo [risk ratio¼ 0.49, 95% confidence interval
(CI): 0.33–0.73, P¼ 0.001]. Results from meta-
regression suggest adherence was a significant moderator
of PrEP effectiveness (regression coefficient¼0.02,
P< 0.001) (Table 2a, Fig. 2). When stratified by
adherence, overall heterogeneity was greatly reduced.
PrEP was most effective in studies with high adherence,
where HIV infection risk was reduced by 70% (risk
ratio¼ 0.30, 95% CI: 0.21–0.45, P< 0.001). PrEP also
significantly reduced infection risk in studies with
moderate adherence levels, but showed no effect in
studies with low adherence (risk ratio¼ 0.95, 95% CI:
0.34–1.23, P¼ 0.70). In studies comparing immediate
with delayed PrEP [42,43], PrEP was protective against
HIV infection (risk ratio¼ 0.15, 95% CI: 0.05–0.46,
P¼ 0.001). Reductions in HIV incidence were also seen
in observational studies (Table 2b) [11,29,41].
When stratified by mode of acquisition, PrEP showed
similar effectiveness across groups (coefficient¼ 0.47,
P¼ 0.36) (Table 2a). The relative risk for HIV infection
comparing PrEP with placebo for rectal exposure was
0.34 (95% CI: 0.15–0.80, P¼ 0.01) and 0.54 (95% CI:
0.32–0.90, P¼ 0.02) for penile/vaginal exposure. Across
other stratifications, PrEP remained significantly protec-
tive against HIV infection. No significant differences in
PrEP effectiveness were seen between sexes, regimens,
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e.and dosing, although effectiveness data for intermittent
PrEP were limited to one study. For PrEP regimens,
results from meta-regression suggest TDF PrEP was as
effective as FTC/TDF PrEP (meta-regression P
value¼ 0.88); this finding remained consistent when
stratified by sex. Similarly, the Partners PrEP Study
Continuation found no difference in HIV-prevention
effectiveness comparing daily FTC/TDF with TDF [40].
Three studies provided age-stratified data (<25 years and
25 years) [18,24,32]. In meta-regression, age did not
moderate the relationship between PrEP and HIV
infection (coefficient¼ 0.45, P¼ 0.29, Table 2a); how-
ever, in stratified analysis PrEP was not statistically
effective for younger participants (risk ratio¼ 0.71, 95%
CI: 0.47–1.06, P¼ 0.07). Several studies noted that
younger participants had poorer adherence compared
with older participants [8,29]. Therefore, while age may
not moderate the relationship between PrEP and HIV
infection, low adherence could explain diminished
effectiveness among young populations.
We also evaluated age and sex-stratified data, which were
reported in two studies, to evaluate PrEP effectiveness
among young women. PrEP was not effective in
preventing HIV infection among women aged less than
25 years in FEM-PrEP [12] but did effectively reduce
infection among women aged less than 30 years in
Partners PrEP [38].
Adverse events
Ten placebo-controlled RCTs presented data on any
adverse event. Across studies, proportions of adverse
events comparing PrEP with placebo were similar (odds
ratio¼ 1.01, 95% CI: 0.99–1.03, P¼ 0.27). No differ-
ences were seen across subgroups based on mode of
acquisition, adherence, sex, drug regimen, dosing, or age
(Table 3). Comparing immediate with delayed PrEP, two
studies reported occasional PrEP interruptions because of
medical events, such as gastrointestinal symptoms, but
noted PrEP was reinitiated in most participants without
event recurrence [29,43]. Regarding drug regimen, the
Partners PrEP Continuation Study found no significant
difference in adverse events comparing FTC/TDF and
TDF [20].
Eleven placebo-controlled RCTs presented results on any
grade 3 or 4 adverse event, proportions of which did not
differ between PrEP and placebo groups (risk
ratio¼ 1.02, 95% CI: 0.92–1.13, P¼ 0.76). No statisti-
cally significant differences were seen across subgroups
(Table 3). Several studies reported small, subclinical
decreases in renal function among PrEP users [9,28].
Although function mostly returned to normal following
PrEP discontinuation. Additionally, some studies
reported small, subclinical decreases in liver function
[8,18], and bone mineral density [15,44] while taking
PrEP.
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Table 2. Meta-analysis results assessing the effectiveness of preexposure prophylaxis in preventing HIV acquisition across subgroups and
metaregression results assessing the impact of subgroup characteristics on effectiveness.
Results from meta-analysis Results from metaregression
Analysis No. of studies Total N
Risk Ratio
(95% CI) P value I2
Meta-regression (MR)
coefficient
MR standard
error MR P value
RCTs comparing PrEP with placebo
Overalla 10 17423 0.49 (0.33–0.73) 0.001 70.9
Mode of Acquisition
Rectal 4 3166 0.34 (0.15–0.80) 0.01 29.1 ref
Vaginal/penileb 6 14252 0.54 (0.32–0.90) 0.02 80.1 0.47 0.51 0.36
Adherence
High (>70%) 3 6149 0.30 (0.21–0.45) <0.001 0.0 1.14 0.23 <0.001
Moderate (41–70%) 2 4912 0.55 (0.39–0.76) <0.001 0.0 0.55 0.21 0.01
Low (40%) 2 5033 0.95 (0.74–1.23) 0.70 0.0 ref
Biological sexc
Men 7 8704 0.38 (0.25–0.60) <0.001 34.5 ref
Women 6 8714 0.57 (0.34–0.94) 0.03 68.3 0.46 0.35 0.19
Age
<25 years 3 2997 0.71 (0.47–1.06) 0.09 20.5 ref
25 years 3 6291 0.45 (0.22–0.91) 0.03 72.4 0.45 0.42 0.29
Drug regimend
TDF 5 8619 0.49 (0.28–0.86) 0.001 63.9 ref
FTC/TDF 7 11381 0.51 (0.31–0.83) 0.007 77.2 0.06 0.40 0.88
Drug dosinge
Daily 8 16951 0.54 (0.36–0.81) 0.003 73.6 ref
Intermittent 1 400 0.14 (0.03–0.63) 0.01 0.0 1.32 0.90 0.14
RCTs comparing PrEP to no PrEP
Overall 2 723 0.15 (0.05–0.46) 0.001 0.0
Table 2b HIV infection outcomes for observational studies.
Study Study N HIV Incidence rate no PrEP HIV Incidence rate OLE PrEP users Comparison
Bangkok
tenofovir OLE
787 0.7 infections per 100 PY
(95% CI: 0.5–1.0)
0.5 infections per 100 PY
(95% CI: 0.02–2.3)
Placebo arm of trial to OLE
iPrEx OLE 1603 2.6 infections per 100 PY
(95% CI 1.5–4.5)
1.8 infections per 100 PY
(95% CI 1.3–2.6)
Non-PrEP users in OLE to PrEP
users in OLE
Partners
demonstration
1013 5.3 infections per 100 PY
(95% CI 3.2–7.6)
0.2 infections per 100 PY
(95% CI 0.0–1.3)
Simulated counterfactual to OLE
aModified intent-to-treat (MITT) analyses are presented.
bThe Bangkok Tenofovir Study contributed data to the penile/vaginal sexual exposure analysis as most participants reported engaging in
heterosexual sex (although infections could have also been because of parenteral transmission).
cStudy populations comprising men and women were disaggregated by sex for this analysis.
dStudies comparing more than one PrEP regimen contributed to both TDF and FTC/TDF groups (data were disaggregated by regimen).
eThe IAVI Kenya study was omitted from this analysis because the trial assessed both daily and intermittent PrEP but it is unclear in which placebo
arm (daily or intermittent) the one HIV infection occurred.
FTC, emtricitabine; OLE, open-label extension; PrEP, preexposure prophylaxis; PY, person year; TDF, tenofovir disoproxil fumarate.Drug resistance
Six trials measured and reported cases of TDF or FTC
drug resistance, identified using standardized clinical
genotypic laboratory assays [8,18,24,32,45,47]. Results
from ultrasensitive analyses were excluded because of lack
of validation for clinical use. Within these trials, eight
(18%) HIV infections with mutations conferring resist-
ance to TDF or FTC occurred among 44 individuals
acutely HIV-infected at enrollment, comprising two
resistant infections among those randomized to placebo
and six among those randomized to PrEP. In addition, six
(2%) TDF or FTC drug-resistant infections occurred out
of 533 cases of incident HIV infection postrandomization
across study arms (Table 2S, http://links.lww.com/
QAD/A928), including five FTC mutations among
those randomized to PrEP and one mutation among those
randomized to placebo.Additional HIV infections had resistance to drugs
unrelated to PrEP, likely because of primary drug
resistance. Definitively distinguishing between primary
and secondary (PrEP-selected) drug resistance was not
possible for most infections.
When comparing PrEP (any regimen) with placebo, risk
of developing FTC and/or TDF mutations was
significantly higher in PrEP vs. placebo groups (risk
ratio¼ 3.34, 95% CI: 1.11–10.06, P¼ 0.03, Table 3S,
http://links.lww.com/QAD/A928) among those acutely
infected at enrollment. When stratified by PrEP regimen,
the risk of having an FTC-related mutation for those
acutely infected at enrollment was significantly higher
among participants randomized to receive FTC/TDF as
compared with placebo (risk ratio¼ 3.72, 95% CI: 1.23–
11.23, P¼ 0.02, Table 3S, http://links.lww.com/QAD/
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Fig. 2. Depicts the fitted meta-regression line of the relation-
ship between trial-level PrEP adherence and PrEP’s effec-
tiveness in preventing HIV acquisition. Trial-level adherence
is measured along the x-axis as the percentage of participants
who received active study drug and had detectable levels of
either TDF or FTC in their blood during the study. Effective-
ness in preventing HIV acquisition is measured along the
y-axis as a log-risk ratio. Each circle represents a study, and
the size of the circle is directly proportional to the study’s size
and weight in meta-regression. PrEP, preexposure prophy-
laxis; TDF, tenofovir disoproxil fumarate.A928). Risk of having a TDF-related mutation was not
statistically different between PrEP and placebo, regard-
less of PrEP regimen, among those acutely infected
at enrollment.
Among participants who seroconverted postrandomiza-
tion, FTC, or TDF resistant infections were uncommon,
leaving little power to assess relative risk. With TDF PrEP,
no seroconverters had resistance to tenofovir in either
placebo or active arms. Across PrEP regimens, statistically
insignificant increases in the proportion of new infections
with FTC or TDF-related mutations comparing PrEP
with placebo (risk ratio¼ 3.14, 95% CI: 0.53–18.52,
P¼ 0.21, Table 3S, http://links.lww.com/QAD/A928)
were found among those who seroconverted postrando-
mization. Results remained insignificant when stratified
by mutation type and PrEP regimen.
Reproductive health
FEM-PrEP and Partners PrEP reported hormonal
contraception effectiveness comparing participants
receiving PrEP vs. placebo [20,39]. In FEM-PrEP,
hormonal contraception use was required for trial
participation. In Partners PrEP, hormonal contraception
use was not required, but monthly study visits included
contraceptive counseling and free on-site contraception
access.
When comparing pregnancy rates among contraceptive
users receiving PrEP and placebo, results from raw datademonstrated higher pregnancy rates for those receiving
PrEP (Table 4S, http://links.lww.com/QAD/A928).
However, because of confounding across study arms
we present separate adjusted pregnancy rates comparing
PrEP and placebo groups (Table 5S, http://links.lww.
com/QAD/A928). In both FEM-PrEP and Partners
PrEP, treatment assignment became an insignificant
predictor of pregnancy when adjusted for confounders
[20,39]. Owing to differing analytic comparisons,
synthesis of adjusted data was infeasible. Both studies
noted higher pregnancy incidence among women taking
combined oral contraceptives compared with injectable
or implantable methods.
FEM-PrEP and Partners PrEP also evaluated effects of
PREP on adverse pregnancy-related events (Table 6S,
http://links.lww.com/QAD/A928). Study drug was
discontinued for women once pregnancy was confirmed
across trials; therefore, the effect of PrEP throughout
pregnancy duration was not assessed. Across studies risk of
adverse pregnancy-related events did not differ between
PrEP and placebo arms (risk ratio¼ 1.25, 95% CI: 0.64–
2.45, P¼ 0.52), and results remained insignificant when
stratified by adherence and PrEP regimen. In the Partners
PrEP Study Continuation, pregnancy loss frequency was
similar between PrEP regimens [35].
Sexual behavior
Condom use was reported in five RCTs comparing PrEP
with placebo [18,24,32,45,48], three RCTs comparing
PrEP with no-PrEP [12,42,43], one observational study
[29], and one longitudinal analysis comparing outcomes
from the placebo-controlled phase and OLE continuation
[36]. Owing to differences in condom use measurement
across studies, meta-analysis was infeasible. However,
studies consistently showed no difference in condom use
across arms (Table 7S, http://links.lww.com/QAD/
A928), and some even showed increases in condom
use throughout trial duration. Among studies comparing
PrEP with no-PrEP, which more accurately reflect real-
life scenarios than placebo-controlled RCTs, studies
similarly found either no change in condom use across
arms or slight increases in condom use over time
[12,13,42]. Notably in PROUD, investigators used
incident sexually transmitted infections (STIs) as a
biological proxy for noncondom sexual intercourse and
found similar rates across immediate and delayed PrEP
arms [13]. The longitudinal Partners PrEP analysis
comparing placebo-controlled RCTwith OLE continu-
ation periods found trends toward decreasing frequency
of noncondom intercourse with HIV-positive study
partners but also noted increased frequency of noncon-
dom intercourse with outside partners over time [36].
Eight placebo-controlled trials, two RCTs comparing
PrEP with no-PrEP, and three observational studies
examined number of sexual partners. Like condom use,
differing measurements precluded meta-analysis;
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Table 3. Meta-analysis results for effects of preexposure prophylaxis on any adverse event.
Any adverse event Any grade 3 or 4 adverse event
Analysis No. of studies Pooled risk ratio (95% CI) P value I2 No. of studies Pooled risk ratio (95% CI) P value I2
RCTs comparing PrEP with placebo
Overall 10 1.01 (0.99–1.03) 0.27 38.1 11a 1.02 (0.92–1.13) 0.76 16.5
Mode of acquisition
Rectal 3 1.01 (0.97–1.06) 0.60 6.0 5 1.09 (0.84–1.41) 0.52 19.0
Vaginal/penile 7 1.01 (0.99–1.04) 0.39 51.6 6 1.00 (0.88–1.15) 0.96 28.9
Adherence
Low 2 0.97 (0.87–1.08) 0.60 85.6 2 1.08 (0.71–1.64) 0.71 58.0
Medium 2 1.01 (0.98–1.04) 0.46 13.9 2 0.95 (0.82–1.10) 0.48 0.0
High 2 1.02 (0.99–1.04) 0.23 28.4 3 1.05 (0.78–1.39) 0.76 51.9
Biological sex
Men 2 1.00 (0.98–1.03) 0.85 0.0 4 1.07 (0.83–1.39) 0.59 22.8
Women 3 1.00 (0.92–1.07) 0.92 80.2 2 1.08 (0.71–1.64) 0.71 58.0
Drug regimen
TDF 4 0.98 (0.92–1.04) 0.47 88.5 3 0.95 (0.80–1.13) 0.56 54.1
FTC/TDF 8 1.02 (1.00–1.04) 0.06 0.0 10 1.07 (0.94–1.21) 0.32 17.4
Drug dosing
Daily 9 1.00 (0.97–1.03) 0.78 65.6 9 1.01 (0.91–1.13) 0.81 21.2
Intermittent 3 1.05 (0.99–1.11) 0.14 0.0 3 1.14 (0.60–2.18) 0.70 0.0
Age No safety data stratified by age No safety data stratified by age
RCTs comparing PrEP to no PrEP
Overall Data not reported for PROUD and CDC Safety Study Data not reported for PROUD; CDC Study included in PrEP
vs. placebo analysis
aThe FEM-PrEP study did not present results for the outcome ‘any grade 3 or 4 event.’ For this analysis, results from the outcome ‘any serious adverse
event’ were used.
PrEP, preexposure prophylaxis.however, results across studies found no evidence that
PrEP impacted participants’ reported number of sexual
partners (Table 8S, http://links.lww.com/QAD/A928).
Among placebo-controlled RCTs, many found small
reductions in sexual partners reported over time
[10,18,45] or no change across study arms [24,31,32].
The IAVI Kenya study was the only trial to find an
increase in sexual partners from baseline to follow-up,
although investigators noted the possibility of partner
underreporting at baseline [30]. When comparing PrEP
with no-PrEP, studies either found decreases in reported
number of sexual partners [12] or no change from
baseline to follow-up among participants [13]. Observa-
tional studies showed similar null results [11,29].Discussion
Evidence summary and implications
This review evaluated the effect of oral PrEP containing
TDF in 15 RCTs and three observational studies. PrEP
was effective in reducing risk of HIV acquisition across
types of sexual exposure, sexes, PrEP regimens, and
dosing schemes. Studies have suggested a possible
biological mechanism for different rates of protection
according to primary transmission route, in that higher
rates of drug concentration have been found in rectal
tissue compared with vaginal; [50,51]; however, we found
no such differences in protective effects. In our analyses,
trial-level adherence moderated the impact of PrEP on
HIV acquisition, as PrEP was more effective in reducing
risk of HIV infection with higher levels of PrEPadherence. Overall, the level of effectiveness within each
study was similar to the proportion of people in the active
arm who had PrEP drug detected, indicating that PrEP is
highly efficacious when used.
The finding that TDF and FTC/TDF have comparable
effectiveness in meta-analysis is consistent with two
clinical placebo-controlled trials that compared the
regimens directly in heterosexual populations [32,47],
and with one study comparing single and dual-agent
PrEP [40]. TDF PrEP for heterosexual populations may
be attractive because of its comparable effectiveness, lower
cost, greater availability, and lower risk of drug resistance
[34]. Only one safety study evaluated TDF PrEP among
MSM; other trials among MSM used FTC/TDF PrEP.
For young women, one study found PrEP was effective in
reducing HIV infection and another study found no
effect, most likely associated with differing levels of
adherence. Results from one open label study demon-
strate that young women can maintain high levels of PrEP
use when aware PrEP is effective [7]. A more recent OLE
completed after our search period also found that women
can be highly adherent to PrEP [52]. Despite this
evidence, gaps exist in knowing how PrEP will be
perceived and used among young people in real-world
settings, and research is needed to understand what
supportive interventions, tailored to young people’s
needs, could be implemented in combination with
PrEP [53]. Promising approaches include providing
information about how well PrEP works when used
properly; building community support for PrEP; allowing
Effectiveness of oral preexposure prophylaxis Fonner et al. 1981choice in contraceptive use; and combining PrEP
programs with social marketing campaigns and adherence
support programs [54].
Regarding safety, PrEP showed no evidence of increased
proportion of adverse events. However, two studies
reported small decreases in renal function among those
taking PrEP [9,28]. PrEP programs have used relatively
intensive monitoring of renal function, including
frequent creatinine testing, which may or may not be
required to assure safety. Several trials demonstrated a
small decrease in bone mineral density during the first
24 weeks of PrEP use that did not progress thereafter,
including one study published after our search that
showed small, reversible decreases in bone mineral density
among African women [55]. Given that HIV infections
occurring in the absence of PrEP would require lifelong
antiretroviral therapy, which is associated with a three to
four-fold greater loss of bone mineral density compared
with PrEP [56], and HIV has direct toxicity to bone [57],
this presents a favorable risk benefit ratio.
The risk of tenofovir or FTC resistance during use of
PrEP was low. In meta-analysis, participants randomized
to PrEP had a higher risk of resistance compared with
placebo among those acutely HIV-infected when starting
PrEP, with more cases of resistance occurring to FTC
than TDF. This is consistent with results from the
Partner’s PrEP Study Continuation that compared the
regimens directly [34]. The risk of drug resistance with
PrEP has to be weighed with overall benefits [58]. If PrEP
had been withheld, more HIV infections would have
occurred, which would require life-long therapy with an
annual risk of drug resistance varying between 5 and 20%.
As such, levels of drug resistance occurring by preventing
HIV infection with PrEP are expected to be less than if
HIV is left unchecked, as predicted by mathematical
modeling [59,60]. How implementing PrEP on a large
scale affects resistance overall is unknown, and active
surveillance is warranted.
Regarding sexual behaviors, we found no evidence that
PrEP led to risk compensation; however, recent results
from real-world PrEP implementation in San Francisco
found a relatively high incidence of STIs and a 41%
decrease in reported condom use among a subset of PrEP
users [61]. RCTs are not well suited to assess risk
compensation as participants’ perceptions of protection
are unknown, particularly as participants are unaware
whether they are receiving an effective, active agent [62].
The lack of risk compensation seen in the OLE studies
provides better evidence regarding risk compensation, as
these scenarios more closely mirror real-world use.
However, these participants also received intensive
behavioral counseling and previously served as trial
participants, suggesting their behavior might be dissimilar
to those taking PrEP outside of a research setting. The
continued reduction in sexual risk behaviors seenacross the OLE studies and demonstration projects speaks
to the potential effectiveness of providing counseling and
other prevention options within the context of PrEP
implementation.
Regarding pregnancy, PrEP does not appear to affect
hormonal contraception effectiveness, although two
studies found trends toward higher rates of pregnancy
among oral contraceptive users who took PrEP. Oral
PrEP was not associated with increased adverse preg-
nancy-related events among women taking PrEP during
early pregnancy.
Limitations
This review has several limitations. Despite comprehen-
sive searching, our strategy may have failed to identify
eligible studies. For included studies, we made efforts to
contact study authors for clarifications when necessary,
but not all investigators were reachable. Behavioral
outcomes were mostly based on self-report, although two
studies [24,32] also reported decreasing rates of STIs and
one study reported decreases in acute HIV infection
prevalence commensurate with reported safer behavior
[27]. Additionally, several outcomes (drug resistance and
pregnancy outcomes) had few numbers of absolute
events, thus leading to imprecision of combined effect
sizes. Although we assessed PrEP’s effectiveness in
preventing sexual acquisition of HIV, we did not examine
parenteral transmission of HIV as only one study, the
Bangkok Tenofovir Study, involved people who inject
drugs. Finally, this review synthesized results from trial-
level data only. Although the statistical techniques we
employed allowed us to draw inferences about factors
affecting PrEP effectiveness overall, not analyzing
individual data prevented us from drawing definitive
conclusions about individual circumstances of PrEP use
and effectiveness.
In conclusion, findings demonstrate oral PrEP containing
TDF is effective in reducing risk of HIV infection among
various populations. There is little evidence of risk
compensation and adverse safety events. For outcomes
with few events, including drug resistance and repro-
ductive health outcomes, active surveillance is needed.
Surveillance for safety is also warranted for PrEP users not
adequately represented in clinical trials, including
adolescents, people with underlying comorbidities
affecting renal function, and transgender people. PrEP
uptake and adherence among people at substantial risk for
HIVare key determinants of impact. Based on a collection
of substantial evidence, including results from this
analysis, a review of PrEP acceptability [63], and cost/
feasibility considerations, WHO expanded its 2014 PrEP
recommendation to support offer of PrEP to all
populations as substantial HIV risk [4]. Best practices
for optimizing PrEP delivery based on clinical practice
and evidence are now needed.
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